INSTITUT CLAUDIUS REGAUD
🇫🇷France
Clinical Trials
122
Active:18
Completed:49
Trial Phases
5 Phases
Phase 1:18
Phase 2:20
Phase 3:8
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (102 trials with phase data)• Click on a phase to view related trials
Not Applicable
50 (49.0%)Phase 2
20 (19.6%)Phase 1
18 (17.6%)Phase 3
8 (7.8%)Phase 4
6 (5.9%)Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
Not Applicable
Not yet recruiting
- Conditions
- Urothelial CarcinomaRenal CancerProstate AdenocarcinomaAdenocarcinoma of EndometriumCutaneous MelanomaSoft Tissue Sarcoma (STS)Nonseminomatous Germ Cell TumorSeminomatous Germ Cell TumorUpper Aerodigestive Tract CarcinomaCervical Carcinoma
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 450
- Registration Number
- NCT06967961
- Locations
- 🇫🇷
Oncopole Claudius Regaud, IUCT-O, Toulouse, France
Prostate Cancer Burden and Heterogeneity Evaluation Towards Liquid Biopsy: a Correlation Study to 18FDCFPyL PET and Patients Outcome
Not Applicable
Not yet recruiting
- Conditions
- Prostate Cancer
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 80
- Registration Number
- NCT06917781
- Locations
- 🇫🇷
IUCT-O, Toulouse, France
Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
Not Applicable
Not yet recruiting
- Conditions
- Metastatic Breast CancerMetastatic Prostate Cancer
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 36
- Registration Number
- NCT06904625
- Locations
- 🇫🇷
IUCT-O, Toulouse, France
Evaluation of the Inflammation-based Index as a Predictive Marker of Clinical and Radiological Response in Patients Treated With Lu-177 Oxodotreotide for Intestinal Neuroendocrine Tumour
Not Applicable
Recruiting
- Conditions
- Intestinal Neuroendocrine Tumor
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 150
- Registration Number
- NCT06876532
- Locations
- 🇫🇷
CHU de Bordeaux, Bordeaux, France
🇫🇷Centre François Baclesse, Caen, France
🇫🇷CHU de Lille, Lille, France
Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Patients Receiving Oral Treatment for Cancer or Malignant Haemopathy (ACCELER PLATFORM)
Not Applicable
Recruiting
- Conditions
- Solid CancerHaematological Malignancies
- First Posted Date
- 2025-01-28
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 33
- Registration Number
- NCT06797037
- Locations
- 🇫🇷
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 22
- Next
News
Breakthrough Breast Cancer Drug Capivasertib Approved for NHS Use
A groundbreaking twice-daily pill called capivasertib (Truqap) has been approved for NHS use, targeting hormone receptor-positive HER2-negative breast cancer by blocking cancer growth mechanisms.